Evidence map›Paper›PMID 31921112›Full record

ArticleFrontiers in immunology2019

Natural Killer Cell-Derived Exosomal miR-3607-3p Inhibits Pancreatic Cancer Progression by Targeting IL-26.

Hongwei Sun, Keqing Shi, Kai Qi, Hongru Kong, Jie Zhang, Shengjie Dai, Wen Ye, Tuo Deng, Qiye He, Mengtao Zhou

RetractedErratum issuedOpen access · goldAbstract readRetracted Publication
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 66 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed, 1 pooled it
4.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

66 citing papers in PubMed, 1 synthesis or guideline pooled it, 94 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Exosomes: Emerging Insights into the Progression of Pancreatic Cancer.International journal of biological sciences · 2024
    Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review

6 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Hongwei SunDepartment of Hepatobiliary Surgery, Key Laboratory of Diagnosis and Treatment of Severe Hepato-Pancreatic Diseases of ZheJiang Province, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Keqing ShiKey Laboratory of Diagnosis and Treatment of Severe Hepato-Pancreatic Diseases of ZheJiang Province, Center of Precision Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Kai QiShanghai Institute of Nutrition and Health, Chinese Academy of Sciences, Shanghai, China.
Hongru KongDepartment of Hepatobiliary Surgery, Key Laboratory of Diagnosis and Treatment of Severe Hepato-Pancreatic Diseases of ZheJiang Province, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Jie ZhangDepartment of Hepatobiliary Surgery, Key Laboratory of Diagnosis and Treatment of Severe Hepato-Pancreatic Diseases of ZheJiang Province, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Shengjie DaiDepartment of Hepatobiliary Surgery, Key Laboratory of Diagnosis and Treatment of Severe Hepato-Pancreatic Diseases of ZheJiang Province, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Wen YeDepartment of Hepatobiliary Surgery, Key Laboratory of Diagnosis and Treatment of Severe Hepato-Pancreatic Diseases of ZheJiang Province, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Tuo DengDepartment of Hepatobiliary Surgery, Key Laboratory of Diagnosis and Treatment of Severe Hepato-Pancreatic Diseases of ZheJiang Province, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Qiye HeSinglera Genomics Inc., San Diego, CA, United States.
Mengtao ZhouKey Laboratory of Diagnosis and Treatment of Severe Hepato-Pancreatic Diseases of ZheJiang Province, Precision Medical Center Laboratory, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
First Affiliated Hospital of Wenzhou Medical University · CNWenzhou Medical University · CNShanghai Institute of Nutrition and Health · CNSinotech Genomics (China) · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Increasing evidences have suggested that natural killer (NK) cells in the tumor microenvironment are involved in the regulation of cancer development. However, the potential biological roles and regulatory mechanisms of NK cells in pancreatic cancer (PC) remain unclear. Co-culture system of NK cells with PC cells is used to test the ability of cancer cell proliferation, migration and invasion both

Indexed as

AnimalsCell LineCells, CulturedDown-RegulationDrug Screening Assays, AntitumorExosomesHumansInterleukinsKiller Cells, NaturalMaleMiceMice, Inbred BALB CNeoplasm InvasivenessPancreatic NeoplasmsIL26 protein, humanInterleukinsextracellular vesiclesIL-26miR-3607-3pnatural killerpancreatic cancer

Identifiers

PMID31921112
PMCPMC6918866
OpenAlexW2995593552

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.